GB2613516A — Formulations of anti-viral compounds
Assigned to Sayvaa Pharmaceuticals Inc · Expires 2023-06-07 · 3y expired
What this patent protects
A pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein X is selected from a hydroxyl, a metal salt hydroxylate, an O-linked phosphoester, an O-linked phosphoramidite, an O-linked ester, an O-linked carbamate, an S-…
USPTO Abstract
A pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein X is selected from a hydroxyl, a metal salt hydroxylate, an O-linked phosphoester, an O-linked phosphoramidite, an O-linked ester, an O-linked carbamate, an S-linked phosphothioate, or an N-linked phosphoramidite, and at least one pharmaceutically acceptable excipient selected from a cysteine compound, an amino acid, an N-acetyl amino acid, an acid or a salt thereof, or any combination thereof. The pharmaceutical composition can be used for the effective treatment of viral infections in humans and other animal species caused by viruses, in particular, RNA viruses and can be administered orally or parenterally.
Drugs covered by this patent
- Veklury (remdesivir) · Gilead Sciences
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.